The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

WPD Pharmaceuticals (‘WPD’) is a biotechnology research and development company focused on developing drug candidates involved in targeted therapy for brain cancers. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. 

IAG, Image Analysis Group (‘IAG’) is a leading medical imaging company and will work closely with WPD to provide critical imaging services, its proprietary platform DYNAMIKA and imaging data analysis to assess the effects of Berubicin in a phase II clinical trial in patients with GBM.

Advanced cancer therapies, such as WPD’s Berubicin treatment, often lead to pseudo-progression, a local tissue reaction resulting from immune cell infiltration, causing inflammation, tumor necrosis and oedema which are often misinterpreted as tumor growth on traditional MRIs.

Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments. This is where non-invasive methods are needed to enhance the understanding of complex neuro-pathologies.

Novel imaging strategies and artificial intelligence (‘AI’) driven imaging biomarkers can advance neuro-oncology clinical trials by providing deep analysis of disease progression and treatment response. They are most efficiently integrated in clinical trials when implemented using a cloud-platform, such as IAG’s DYNAMIKA, that combines central review of standard radiographic endpoints, such as Response Assessment in Neuro-Oncology (‘RANO’), as well as advanced imaging endpoints in a cost and time efficient fashion.

Register for this joint webinar from WPD and IAG to learn more about Berubicin and how the development of novel brain cancer therapies can be advanced with the use of AI and efficient imaging data management.

Speakers

Mariusz Olejniczak, CEO at WDP Pharmaceuticals

Mariusz Olejniczak is a graduate of Biotechnology at the University of Life Sciences in Poznań, an experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage – from planning and scientific advice through supervision to the closure and finalization of the project, a founder of several start-ups in the e-health industry and a member of the board and supervisory board of several R&D companies. Mariusz Olejniczak is also the author of the publication “Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish), and a member of the editorial committee of the book “Clinical Trials” (in Polish), as well as a lecturer in postgraduate study programs.

 

 

 

Message Presenter

Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer at IAG, Image Analysis Group

Dr. Diana Dupont-Roettger is a Medical Computer Scientist by background with strong experience in novel imaging technologies, AI and imaging markers and their role in clinical trials. She advises biopharmaceutical companies on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications.

 

 

 

 

Message Presenter